A Phase 3 interventional study of Dapagliflozin and Metformin XR in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 123 sites in 6 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2016-07-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 11 that started in 2009, is one of 47 in phase 3, and was the 20th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,093 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 23rd largest by enrollment of the 280 interventional ones that give a count, is one of 43 that started in 2009, is one of 119 in phase 3, and was the 116th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
\<= 77 years old, with type 2 diabetes mellitus
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks
Drug: Dapagliflozin · Drug: Metformin XR
Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks. Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks.
Drug: Dapagliflozin · Drug: metformin HCl Modified Release matching Placebo
Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks
Drug: Metformin XR · Drug: dapagliflozin matching Placebo
Tablets, Oral, 10 mg, once daily, 24 weeks
Also known as: Farxiga™
Tablets, Oral, up to 2000 mg, once daily, 24 weeks
Also known as: Glucophage®
Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
Also known as: Glucophage®
Tablets
Tablets
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants
Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.
Time frame: Week 24
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants
Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.
Time frame: Week 24
Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants
Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.
Time frame: Week 24
Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%
HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Time frame: Week 24
The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants
Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.
Time frame: Week 24
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants
Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.
Time frame: Day 1 of Double Blind Period to end of Week 24 Plus 30 days
Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants
Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.
Time frame: Baseline to last dose plus 4 days in 12 Week Double Blind Period
Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants
Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Time frame: Week 24
Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants
Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
Time frame: Week 24
Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants
12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.
Time frame: Week 24
Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants
Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \<6 (\>18 females or \>20 males) g/dL; hematocrit \<20% ( \>55% females or \>60% males); creatinine (\>=1.5\*preRX, \>=2.5 mg/dL); glucose \<54 (\>350) mg/dL; creatine kinase (\>5\*ULN);calcium \<7.5 (\>=1 mg/dL from ULN and \>= 0.5mg/dL from PreRX); sodium \<130 or \< 120 male/female (\>150 mEq/L; potassium \<=2.5 (\>=6.0) mEq/L; bicarbonate \<= 13 mEq/L; inorganic phosphorus: \<=1.8 if age 17-65 or \<=2.1 if age \>=66, (\>=5.6 if age 17-65 or \>=5.1) mg/dL if age \>=66; albumin \<=2 (\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\>1800 mg/g)
Time frame: Baseline to Week 24/end of treatment plus 4 days
Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants
Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\>) less than (\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\>3\*ULN); bilirubin (\>2\*ULN if PreRX \<= ULN; \>3\*ULN if PreRX \> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \>3\*ULN and bilirubin \>1.5\*ULN within 14 days on or after ALT elevation.
Time frame: Baseline to Week 24/end of treatment plus 30 days
Participants were recruited from 13-April-2009 to 26-November-2009. Study completed 12-May-2010. Drug naive participants with Type 2 Diabetes Mellitus who had inadequate glycemic control with diet and exercise. Inadequate glycemic control was defined as a hemoglobin A1c (HbA1c) ≥ 7.5% and ≤ 12.0%.
| Milestone | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Started | 211 | 219 | 208 |
| Completed | 183 | 188 | 181 |
| Not completed | 28 | 31 | 27 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 |
| Withdrew: Adverse event | 4 | 9 | 8 |
| Withdrew: Withdrawal by subject | 11 | 8 | 11 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 10 | 11 | 5 |
| Withdrew: Poor/non-compliance | 2 | 0 | 0 |
| Withdrew: No longer meets criteria | 0 | 1 | 0 |
| Withdrew: Non-specified | 1 | 1 | 1 |
Adjusted mean change in HbA1c from baseline at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available, ie, last observation carried forward (LOCF) was determined. HbA1c was measured as percent of hemoglobin by a central laboratory. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. HbA1c measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 4, 8, 12, 16, 20, and 24 in the Double-Blind Period.
| Percent of hemoglobin | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants | -1.98 ± 0.0759 | -1.45 ± 0.0734 | -1.44 ± 0.0757 |
Data after rescue medication was excluded from this analysis. FPG was measured as milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. FPG measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.
| mg/dL | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants | -60.4 ± 2.533 | -46.4 ± 2.494 | -34.8 ± 2.545 |
Therapeutic glycemic response was defined as HbA1c less than 7.0%. n=Number of participants with HBA1c less than (\<) 7 % at Week 24, last observation carried forward (LOCF) while N=number of randomized participants with non-missing baseline and Week 24 (LOCF) values. Percent=n/N and was adjusted for Baseline HbA1c. Data after rescue medication was excluded from this analysis. HbA1c was measured as a percent of hemoglobin.
| Percent of participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants | 46.6 (40.1 to 53.0) | 31.7 (25.7 to 37.7) | 35.5 (28.8 to 41.7) |
HbA1c was measured as percent of hemoglobin by a central laboratory. The population included those randomized, treated participants whose Baseline HbA1c was greater than, equal to (\>=) 9.0%. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
| Percent of Hemoglobin | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0% | -2.59 ± 0.1249 | -2.14 ± 0.1305 | -2.05 ± 0.1318 |
Adjusted mean change from baseline in total body weight at Week 24 (or the last post-baseline measurement prior to Week 24 if no Week 24 assessment was available was determined. Data after rescue medication was excluded from this analysis. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication. Body weight was measured in kilograms (kg). Body weight measurements were obtained during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of the Double-Blind Period.
| kg | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants | -3.33 ± 0.2401 | -2.73 ± 0.2346 | -1.36 ± 0.2408 |
Medical Dictionary for Regulatory Activities (MedDRA), version 12.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Data after rescue included.
| participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Adverse Event (AE) | 126 | 132 | 118 |
| Related Adverse Event | 34 | 47 | 32 |
| Serious Adverse Event (SAE) | 3 | 5 | 4 |
| Related SAE | 0 | 1 | 1 |
| Discontinued due to AE | 4 | 9 | 8 |
| Deaths | 0 | 0 | 1 |
| Discontinued due to SAE | 0 | 1 | 1 |
Participants with AEs of hypoglycemia, cardiac/vascular disorders, renal impairment or failure, volume depletion (hypotension/dehydration/hypovolemia), fractures, urinary stones, and other reports suggestive of genital infection or urinary tract infection (UTI) were summarized using MedDRA version 13.0. Data after rescue included for all special AEs except hypoglycemia (excluded data after rescue). Major hypoglycemic episode: symptomatic requiring 3rd party assistance due to severe impairment in consciousness or behavior with a glucose value \< 54 mg/dL and prompt recovery after glucose/glucagon; Minor: either symptomatic with glucose measurement \< 63 mg/dL, regardless of need for 3rd party assistance, or asymptomatic with glucose \< 63 mg/dL that does not qualify as major; Other: suggestive but not meeting criteria for major or minor.
| participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Cardiac Disorder AEs | 3 | 3 | 5 |
| Vascular Disorder AEs | 4 | 10 | 8 |
| Hypoglycemia AEs (excluding data after rescue) | 7 | 2 | 6 |
| Hypoglycemia Major Episode | 0 | 0 | 0 |
| Hypoglycemia Minor Episode | 1 | 0 | 1 |
| Hypoglycemia Other Episode | 6 | 2 | 5 |
| AEs Suggestive of Genital Infection | 18 | 28 | 5 |
| AEs Suggestive of UTI | 16 | 24 | 9 |
| AEs of Renal Impairment or Failure | 2 | 4 | 1 |
| AEs of Hypotension | 0 | 1 | 0 |
| AEs of Syncope | 0 | 1 | 0 |
| AEs of Fracture | 2 | 1 | 0 |
| AEs of Urinary Stones | 0 | 0 | 1 |
Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Blood pressure values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently through out the study. Systolic and Diastolic pressures were measured in millimeters of mercury (mmHg). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
| mmHg | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Systolic (N=182, 185, 179) | -3.3 ± 0.947 | -4.0 ± 0.883 | -1.2 ± 1.010 |
| Diastolic (N=182, 185, 179) | -1.8 ± 0.579 | -1.9 ± 0.525 | 0.0 ± 0.606 |
Measurements were taken during the Qualification and Lead-In Periods and on Day 1 and Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 in the Double Blind Period. Heart rate values were obtained: after the participant was seated quietly for 5 minutes; at least 8 hours after the last ingestion of caffeine, alcohol, or nicotine; and in the same arm (right or left) consistently throughout the study. Heart rate was measured in beats per minute (bpm). Data after rescue were also included. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. In cases where time of the first dose or time of the assessment was not available, baseline was defined as the last assessment on or prior to the date of the first dose of the double-blind study medication.
| bpm | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants | 0.6 ± 0.607 | -0.1 ± 0.593 | 0.5 ± 0.594 |
12-Lead electrocardiograms (ECGs) were performed at entry into Lead-In Period Day -7 visit and Week 24/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator. Baseline (BL) was Day -7 for this parameter. Data after rescue included.
| participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Normal at BL, Normal at Week 24 (N=211, 219, 208) | 101 | 107 | 94 |
| Abnormal BL, Normal at Week 24 (N=211, 219, 208) | 15 | 13 | 22 |
| Normal BL, Abnormal at Week 24 (N=211, 219, 208) | 18 | 8 | 9 |
| Abnormal BL, Abnormal at Week 24 (N=211, 219, 208) | 53 | 68 | 59 |
| Normal at BL, Not Reported at Week 24 | 19 | 15 | 15 |
| Abnormal at BL, Not Reported at Week 24 | 5 | 8 | 8 |
| Not Reported at BL, Abnormal at Week 24 | 0 | 0 | 1 |
Laboratory samples: Qualification and Lead-In Periods, Day 1, Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 of Double-Blind Period. Baseline (BL)=last assessment prior to start of first dose of double-blind study medication. Data after rescue included. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); Units per liter (U/L), blood urea nitrogen (BUN). Marked abnormality Low (High) defined: hemoglobin \<6 (\>18 females or \>20 males) g/dL; hematocrit \<20% ( \>55% females or \>60% males); creatinine (\>=1.5\*preRX, \>=2.5 mg/dL); glucose \<54 (\>350) mg/dL; creatine kinase (\>5\*ULN);calcium \<7.5 (\>=1 mg/dL from ULN and \>= 0.5mg/dL from PreRX); sodium \<130 or \< 120 male/female (\>150 mEq/L; potassium \<=2.5 (\>=6.0) mEq/L; bicarbonate \<= 13 mEq/L; inorganic phosphorus: \<=1.8 if age 17-65 or \<=2.1 if age \>=66, (\>=5.6 if age 17-65 or \>=5.1) mg/dL if age \>=66; albumin \<=2 (\>6) g/dL; urine albumin(alb) / creatinine (creat) ratio (\>1800 mg/g)
| participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| Hematocrit High > 55% (N=209, 218, 206) | 1 | 4 | 1 |
| Hemoglobin High >18 g/dL(N=209, 218, 207) | 5 | 4 | 1 |
| Creatinine >1.5*PreRX (N=209, 218, 207) | 8 | 2 | 5 |
| Glucose High > 350 mg/dL (N=209, 218, 207) | 1 | 2 | 3 |
| Albumin low or high (N=209, 218, 207) | 0 | 0 | 0 |
| Calcium Low <7.5mg/dL (N=209, 218, 207) | 1 | 2 | 1 |
| Calcium High >=1mg/dL+ULN (N=209, 218, 207) | 0 | 2 | 0 |
| Bicarbonate Low <=13mEq/L (N=209, 218, 207) | 3 | 0 | 0 |
| Potassium High >=6 mEq/L (N=209, 218, 207) | 2 | 3 | 6 |
| Sodium Low <130 mEq/L (N=209, 218, 207) | 2 | 2 | 2 |
| Sodium High >150 mEq/L (N=209, 218, 207) | 5 | 5 | 2 |
| Sodium Low <120 mEq/L (N=209, 218, 207) | 0 | 1 | 0 |
| inorganic phosphorus (high)(N=209, 218, 207) | 7 | 13 | 3 |
| Urine albumin/creat ratio (high)(N=209, 218, 206) | 0 | 3 | 1 |
Safety laboratory measurements were obtained during the Qualification and Lead-In Periods and on Day 1 of the Double-Blind Period and at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24. BL was defined as the last assessment prior to the start of the first dose of the double-blind study medication. Data included from BL up to and including the last day of treatment plus 30 days. Liver function abnormality criteria: FDA Guidance for Industry: Premarketing Clinical Evaluation (July 2009). Data after rescue was also included. Abbreviations: Pretreatment (PreRX), upper limit of normal (ULN); greater than (\>) less than (\<); Units per liter (U/L), alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality Low (High) defined: ALP, AST and ALT (\>3\*ULN); bilirubin (\>2\*ULN if PreRX \<= ULN; \>3\*ULN if PreRX \> ULN); AST or ALT plus (+) bilirubin elevation: AST or ALT \>3\*ULN and bilirubin \>1.5\*ULN within 14 days on or after ALT elevation.
| participants | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR |
|---|---|---|---|
| AST >3*ULN (N=210, 219, 208) | 2 | 3 | 2 |
| AST >5*ULN (N=210, 219, 208) | 0 | 1 | 1 |
| ALT >3*ULN (N=210, 219, 208) | 2 | 4 | 7 |
| ALT >5*ULN (N=210, 219, 208) | 0 | 1 | 2 |
| ALT >10*ULN (N=210, 219, 208) | 0 | 0 | 1 |
| AST or ALT > 3*ULN (N=210, 219, 208) | 3 | 5 | 7 |
| AST or ALT > 5*ULN (N=210, 219, 208) | 0 | 1 | 2 |
| AST or ALT > 10*ULN (N=210, 219, 208) | 0 | 0 | 1 |
| Total bilirubin >1.5*ULN (N=210, 219, 207) | 0 | 2 | 1 |
| AST or ALT + Bilirubin (High) (N=210, 219, 208) | 0 | 0 | 1 |
| ALP >1.5*ULN (N=210, 219, 208) | 5 | 4 | 3 |
| ALP >3*ULN (N=210, 219, 208) | 0 | 0 | 1 |
Collected over 24 Weeks plus 30 days; Day 1 of double blind treatment to last patient, last visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin | — | 5/219 (2.3%) | 32/219 (14.6%) |
| Dapagliflozin + Metformin XR | — | 3/211 (1.4%) | 26/211 (12.3%) |
| Metformin XR | — | 4/208 (1.9%) | 24/208 (11.5%) |
| Event | Dapagliflozin | Dapagliflozin + Metformin XR | Metformin XR |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 1/219 | 0/211 | 2/208 |
| Myocardial infarctionCardiac disorders | 0/219 | 1/211 | 1/208 |
| Back painMusculoskeletal and connective tissue disorders | 0/219 | 0/211 | 1/208 |
| PainGeneral disorders | 0/219 | 0/211 | 1/208 |
| Angina unstableCardiac disorders | 0/219 | 1/211 | 0/208 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/219 | 1/211 | 0/208 |
| Lung abscessInfections and infestations | 1/219 | 0/211 | 0/208 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/219 | 0/211 | 0/208 |
| RectoceleReproductive system and breast disorders | 1/219 | 0/211 | 0/208 |
| PneumoniaInfections and infestations | 1/219 | 0/211 | 0/208 |
| Event | Dapagliflozin | Dapagliflozin + Metformin XR | Metformin XR |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/219 | 15/211 | 20/208 |
| Urinary tract infectionInfections and infestations | 17/219 | 6/211 | 4/208 |
| Vulvovaginal mycotic infectionInfections and infestations | 11/219 | 7/211 | 1/208 |
All randomized participants who took at least one dose of double-blind study medication.
| Age, Continuous(years) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Mean | 51.0 ± 10.13 | 51.1 ± 11.53 | 52.7 ± 10.38 | 51.6 ± 10.72 |
| Age, Customized(participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Less than (<) 65 years | 190 | 192 | 181 | 563 |
| Greater than, equal to (>=) 65 and < 75 years | 21 | 24 | 25 | 70 |
| >= 75 years | 0 | 3 | 2 | 5 |
| Not Reported | 0 | 0 | 0 | 0 |
| Age, Customized(participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Female <= 50 years | 43 | 44 | 44 | 131 |
| Female > 50 years | 62 | 70 | 67 | 199 |
| Sex: Female, Male(Participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Female | 105 | 114 | 111 | 330 |
| Male | 106 | 105 | 97 | 308 |
| Ethnicity (NIH/OMB)(Participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Hispanic or Latino | 34 | 34 | 35 | 103 |
| Not Hispanic or Latino | 54 | 63 | 54 | 171 |
| Unknown or Not Reported | 123 | 122 | 119 | 364 |
| Race/Ethnicity, Customized(participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| White | 174 | 176 | 166 | 516 |
| Black/African American | 11 | 13 | 8 | 32 |
| Asian | 24 | 27 | 31 | 82 |
| Other Race | 2 | 3 | 3 | 8 |
| Body Mass Index(participants) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| < 25 kg/m^2 | 20 | 25 | 21 | 66 |
| >= 25 kg/m^2 - <27 kg/m^2 | 23 | 24 | 20 | 67 |
| >= 27 kg/m^2 - <30 kg/m^2 | 45 | 39 | 49 | 133 |
| >= 30 kg/m^2 | 123 | 131 | 118 | 372 |
| Waist Circumference(cm) | Dapagliflozin + Metformin XR | Dapagliflozin | Metformin XR | Total |
|---|---|---|---|---|
| Mean | 104.33 ± 13.678 | 103.86 ± 12.805 | 103.03 ± 13.224 | 103.75 ± 13.225 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 123 sites across 6 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Metformin